Drug intelligence / Profile preview

GFT1575

Development stage: Preclinical
Lead developer: Genfit
Modality: Small Molecules

Overview

GFT1575 is an investigational **small-molecule pan-peroxisome proliferator-activated receptor agonist** being developed by GENFIT for liver disease, particularly acute-on-chronic liver failure. Publicly available company disclosures describe it as a proprietary **pan-PPAR agonist** that has been evaluated in preclinical acute-on-chronic liver failure-related programs alongside other GENFIT liver assets. Detailed public information on its exact receptor isoform potency profile, formulation, and clinical pharmacology remains limited, and the asset appears to remain in **preclinical development** rather than advanced clinical testing.

Targets

PPARD (Peroxisome proliferator–activated receptor delta)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on GFT1575.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GFT1575.

Explore the full profile